AstraZeneca PLC Directorate Change (0963O)
August 16 2017 - 1:00AM
UK Regulatory
TIDMAZN
RNS Number : 0963O
AstraZeneca PLC
16 August 2017
16 August 2017 07:00 BST
ASTRAZENECA NON-EXECUTIVE DIRECTOR RETIREMENT
AstraZeneca announced that, on 31 August 2017, Bruce Burlington
will retire as a Non-Executive Director of AstraZeneca PLC and as a
member of the Audit Committee, the Nomination and Governance
Committee, and from his role as Chairman of the Science
Committee.
Dr Burlington joined the Board in 2010 and will have served for
seven years when he steps down.
Leif Johansson, Chairman of AstraZeneca, said: "Bruce has been
an exemplary Director who has made a significant contribution to
the Board's work over many years. We have valued his insightful and
frank participation as a Board member, and Chairman of the Science
Committee during a period of innovation-led transformation at
AstraZeneca. His diligence and commitment to the work of the Audit
Committee and the Nomination and Governance Committee should also
be acknowledged. On behalf of all Board members, we will miss Bruce
as a colleague and send him our very best wishes for the
future."
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Relations
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Nick Stone Respiratory, Brilinta +44 203 749 5716
Christer Gruvris Diabetes; Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOASFSESIFWSESA
(END) Dow Jones Newswires
August 16, 2017 02:00 ET (06:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024